Roth Capital Downgrades Cyclacel Pharmaceuticals (CYCC) to Neutral
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 42
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 42
Join SI Premium – FREE
Roth Capital downgraded Cyclacel Pharmaceuticals (NASDAQ: CYCC) from Buy to Neutral with a price target of $1.00.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Papa John\'s (PZZA) to Underperform, 'Management turnover increases NT uncertainty'
- Evercore ISI Downgrades Sun Life Financial (SLF) to In Line on YTD performance
- Keefe, Bruyette & Woods Downgrades Porch Group Inc. (PRCH) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
